Healthcare provider profile · identity verified

Charles Martin Sackmann, MD

Allopathic & Osteopathic Physicians|Family Medicine · RITZVILLE, WA · NPI 1396759635

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Charles Martin Sackmann, MD received $18.48 in general payments during 2025 across 1 reported records.

Verona Pharma, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.48

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Verona Pharma, Inc. Unresolved — no canonical attribution shown $18.48100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$18.481

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Ohtuvayre
Normalized: ohtuvayre
Drug Verona Pharma, Inc. $18.48 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Losartan PotassiumLosartan Potassium33678
Levothyroxine SodiumLevothyroxine Sodium18150
LisinoprilLisinopril17551
Metformin HclMetformin Hcl16945
GabapentinGabapentin13534
Pantoprazole SodiumPantoprazole Sodium13131
Rosuvastatin CalciumRosuvastatin Calcium13035
Albuterol Sulfate HfaAlbuterol Sulfate11541
Atorvastatin CalciumAtorvastatin Calcium9430
HydrochlorothiazideHydrochlorothiazide9429
IrbesartanIrbesartan9424
Tamsulosin HclTamsulosin Hcl8825
Amlodipine BesylateAmlodipine Besylate8527
FurosemideFurosemide8122
Pravastatin SodiumPravastatin Sodium8021
Fluticasone PropionateFluticasone Propionate7717
EliquisApixaban7514
Metoprolol SuccinateMetoprolol Succinate7419
OmeprazoleOmeprazole7120
MeloxicamMeloxicam7024
Potassium ChloridePotassium Chloride7019
FarxigaDapagliflozin Propanediol6312
ChlorthalidoneChlorthalidone6119
BaclofenBaclofen6017
Metoprolol TartrateMetoprolol Tartrate6020
AllopurinolAllopurinol5814
PrednisonePrednisone5718
FamotidineFamotidine5617
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen5611
Warfarin SodiumWarfarin Sodium5613
CefdinirCefdinir4936
SimvastatinSimvastatin4514
Sertraline HclSertraline Hcl42suppressed
CarvedilolCarvedilol4012
SynthroidLevothyroxine Sodium4012
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip3724
AzithromycinAzithromycin3631
Lantus SolostarInsulin Glargine,hum.Rec.Anlog3511
Doxazosin MesylateDoxazosin Mesylate33suppressed
Ropinirole HclRopinirole Hcl33suppressed
Citalopram HbrCitalopram Hydrobromide32suppressed
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31suppressed
TorsemideTorsemide30suppressed
MupirocinMupirocin2919
XareltoRivaroxaban29suppressed
Duloxetine HclDuloxetine Hcl27suppressed
LorazepamLorazepam27suppressed
Arnuity ElliptaFluticasone Furoate26suppressed
ClopidogrelClopidogrel Bisulfate26suppressed
Fluoxetine HclFluoxetine Hcl25suppressed
JardianceEmpagliflozin25suppressed
Montelukast SodiumMontelukast Sodium25suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid25suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24suppressed
Buspirone HclBuspirone Hcl23suppressed
CephalexinCephalexin2318
GlipizideGlipizide23suppressed
NystatinNystatin2311
OzempicSemaglutide22suppressed
CefuroximeCefuroxime Axetil2115
Donepezil HclDonepezil Hcl21suppressed
Doxycycline MonohydrateDoxycycline Monohydrate2116
Terazosin HclTerazosin Hcl21suppressed
Breo ElliptaFluticasone/Vilanterol20suppressed
Ventolin HfaAlbuterol Sulfate2011
AmoxicillinAmoxicillin1916
NitrofurantoinNitrofurantoin Macrocrystal17suppressed
Solifenacin SuccinateSolifenacin Succinate17suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1612
AtenololAtenolol16suppressed
LovastatinLovastatin16suppressed
SpironolactoneSpironolactone16suppressed
Trazodone HclTrazodone Hcl16suppressed
Dicyclomine HclDicyclomine Hcl15suppressed
Oxybutynin ChlorideOxybutynin Chloride15suppressed
Paroxetine HclParoxetine Hcl15suppressed
Pulmicort FlexhalerBudesonide15suppressed
EzetimibeEzetimibe14suppressed
Glipizide ErGlipizide14suppressed
Midodrine HclMidodrine Hcl14suppressed
Oxycodone HclOxycodone Hcl13suppressed
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide12suppressed
Dilt-XrDiltiazem Hcl12suppressed
FinasterideFinasteride12suppressed
LevetiracetamLevetiracetam12suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12suppressed
Quetiapine FumarateQuetiapine Fumarate12suppressed
Zolpidem TartrateZolpidem Tartrate12suppressed
DigoxinDigoxin11suppressed
EstradiolEstradiol11suppressed
FluconazoleFluconazole11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $18.48 · 1 records Verona Pharma, Inc. Ohtuvayre
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error